Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015's recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options. Implications for policy makers • Determination of the most cost-effective strategy for the moderate to severe psoriasis patients in Malaysia. • Topical and biologic (TB) intervention exhibited highest total cost which was RM434 296.15 (US$124 144.50). • Topical and systemic (TS) treatment was the most cost effectiveness treatment with the lowest cost per psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5 which was RM9034.56 (US$2582.55).
Implications for policy makers
• Determination of the most cost-effective strategy for the moderate to severe psoriasis patients in Malaysia.
• Topical and biologic (TB) intervention exhibited highest total cost which was RM434 296.15 (US$124 144.50).
• Topical and systemic (TS) treatment was the most cost effectiveness treatment with the lowest cost per psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5 which was RM9034.56 (US$2582.55).
• TS appeared to the most cost-effective treatment in the situation where majority of the patients were moderate psoriasis (PASI >10-20, BSA >10-30 and DQLI >10-20).
• The findings will help policy makers in allocation of the resources for the betterment of the psoriasis management in Malaysia.
Implications for the public
This is the first study conducted in Malaysia to measure cost, effectiveness and cost effectiveness of 3 psoriasis interventions namely; topical and phototherapy (TP), topical and systemic (TS), topical and biologic (TB). TP modality was associated with highest loss of productivity cost, RM152 940.00 (US$43 718.23) or 59% of the total productivity costs. TS incurred highest monitoring costs, which was RM37 676.40 (US$10 769.88) or 69% of the total lab tests cost. Meanwhile, TB yielded greatest cost of medication, RM410 118.87 (US$117 233.38) or 67% of the total medication cost. In terms of effectiveness, TB showed the highest (66.7%) while TS appeared to be the most cost-effective treatment with RM9,034.56 (US$2582.55)/ psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5. The findings of this study will help policy-makers in determining appropriate resource allocation for psoriasis management in Malaysia as well as adoption of better strategy considering cost and effectiveness.
Background
Psoriasis is a skin disease characterized by a dry and thick silvery scaling on its surface. Occurring worldwide, it affects 7.5 million Americans equivalent to 2% to 4% of its population, 1 2.8% of the UK population, 2 0.19% to 0.24% in Taiwan, and 0.4% in China. 3 In Malaysia specifically, a total of 17 071 patients with psoriasis from 24 dermatology centres (20 government hospitals, 2 private centres and 2 university hospitals) were registered in Malaysia Psoriasis Registry during the period of 2007 until 2016. 4 For a majority of the cases, it typically begins at the age of 20-35 years old and synonymous with a paramount effect upon the quality of one's life, comparable to other chronic diseases like cancer, hypertension, heart disease and diabetes. 5, 6 Psoriasis is also associated with various comorbidities, such as non-alcoholic fatty liver disease (ie, the most prevalent comorbidity in western countries), 7 obesity, hypertension, dyslipidaemia and diabetes, 8, 9 and mental illness. 10 Therefore, various treatment regimens have been outlined for cases of moderate to severe psoriasis, which includes phototherapy, systemic and biologic methods. In many cases, topical agents are generally used as co-medications to reduce the side effects and enhance the effectiveness of the treatments. Then, phototherapy utilises UV light to absorb into the skin and reduce cell proliferation, and induce T cells and keratinocyte apoptosis. 11, 12 Meanwhile, systemic medications are prescription drugs that affect the entire body and given to patients who are nonresponsive to phototherapy. 6 These systemic agents and its usage should be decided with consideration of their dosage, safety and side effects. 13, 14 In contrast to systemic treatment, biologic treatment functions by reducing symptoms of the disease by targeting a specific immune pathway. Commonly considered as the best discovery in the management of moderate to severe psoriasis, most biologic agents have demonstrated high safety profiles without causing toxicity in the organs. 15, 16 These agents are widely used in Spain, with 19.4% of the total psoriasis patients being prescribed with it, followed by the United Kingdom (9.1%), and France (8.4%). 17 However, the number of patients receiving this type of treatment is still limited in Malaysia.
The different treatment modalities are distinguishable due to their significant effects on the overall cost. Despite being highly efficacious, biologic therapy is particularly attributable to sizable incremental costs, thus resulting in a considerable financial impact. 18, 19 For systemic treatment, the overall cost of the treatment is increased by the need for screening and monitoring tests to be done prior so as to identify any risks of toxicity developing. Meanwhile, phototherapy is particularly limiting as it causes significant loss of productivity due to patients who may have to take off days to get their treatment at the outpatient clinic, amounting to twice or 3 times a week. An estimated 15%-20% of patients have reported to experience reduced of working ability, [20] [21] [22] [23] whereas a staggering 49% of them have missed their working days due to psoriasis. 24 Given the considerable economic impact of psoriasis towards patients and hospitals alike, this has rendered an economic analysis comparing the cost-effectiveness of these treatment modalities to be imperative. However, most of the available studies are reported to be either of low quality and short time duration, using non-comparable effectiveness measures, recorded incomplete cost calculation, or lacks a sensitivity analysis. 25 Moreover, differences in methodological criteria for the studies have also yielded inconclusive findings. To date, no study has yet attempted to measure the costeffectiveness of psoriasis treatment modalities in this region. Thus, the objective of this study is to evaluate the costeffectiveness of 3 psoriasis treatment modalities from the societal perspective, namely: topical and phototherapy (TP), topical and systemic (TS), topical and biologic (TB). Measure of Effectiveness Effectiveness was measured based on the PASI, BSA, and DLQI scores. The specific indicator of effectiveness was PASI-75 (75% improvement over the baseline score) and/or BSA <5 (affected area has reduced) and/or DLQI ≤5 (disease has minimal impact on quality of life), 6 months after treatment is initiated.
Methods

Design and Setting
Cost Analysis An economic evaluation was conducted to calculate costs associated with the management of moderate to severe psoriasis, effectiveness and cost-effectiveness of all 3 modalities over a period of 6-months. Discounting for future costs and results was not applied in cost analysis because both cost and effective outcomes occurred at the same period of time (maximum of 6 months). 12 The total costs of managing moderate to severe psoriasis were calculated from societal's perspective. All costs were presented in Malaysian Ringgit (RM) 2015. From provider's perspective, cost of medication, lab tests and radiology were included. Meanwhile, patient's costs include out-of-pocket expenses and transportation (direct cost) and loss of productivity (indirect cost). Loss of productivity was measured using human capital approach (calculated as; daily income/number of days of patients were unable to work). Medication cost was calculated based on the unit price of drug year 2015 and this information was obtained from the hospital's administrative. Cost of phototherapy, lab tests and radiological procedure were estimated using the Ministry of Health's Fee Act 1951 (revised 1982) for Ministry of Health hospitals (Hospital Kuala Lumpur, Hospital Pulau Pinang, Hospital Sultanah Bahiyah, and Hospital Sultanah Aminah) 28 and charges posed by Universiti Kebangsaan Malaysia Medical Centre. Details of medication, lab tests and radiology were explained in the previous study. 29 All were added to provide total cost of medication. Patient costing form provided primary data for patient out-of-pocket expenditures, transportation and time taken off work, for a duration of 6 month after being recruited into the study. The cost effectiveness was measured by the cost per PASI-75 and/ or BSA <5 and/or DLQI ≤5 achieved. This was calculated by dividing the total cost by the number of patients who achieved this response. Then, a sensitivity analysis has been conducted to resolve any uncertainties behind the input parameters, by integrating variability in the results and producing confidence intervals for each strategy. This has been done to determine and evaluate the robustness of the outcomes towards variations in the final decision model. A scenario analysis based on 3 cases (ie, best, base, and worst case) has also been constructed by applying a 15% variation into both critical variable, cost and effectiveness (into average cost and effectiveness) and this was similar to the previous study done by Vañó-Galván et al. 11 One-way analysis has also been conducted by applying ± 15% on every variable in the study such as cost of medication (ie, systemic, biologic), cost of lab tests and radiology, loss of productivity, probability of effectiveness (PASI-75 and/or BSA <5 and/or DLQI ≤5), cost of transportation and out-ofpocket expenses to determine the most sensitive parameter the model. Statistical analysis was performed using version 21.0 of the Statistical Package for Social Sciences (SPSS Inc.) and Microsoft Excel 2010 for the cost analysis.
Results
A total of 90 moderate to severe psoriasis patients were included in the study. The demographic characteristics of the respondents are shown in Table 1 (Figure 1) . Table 2 presents the total costs associated with psoriasis treatments over a 6-month period. TB has been found Table 2 ). Figure 2 demonstrates cost according to the components for each modality. TB treatment has produced highest total cost of medication which was RM410 118.87 (RM34 176.57/ patient), TS has generated highest total cost of lab tests and transportation which was RM37 676.40 (RM627.94/patient) and RM7160.00 (RM119.33), respectively. Meanwhile, TP treatment has yielded greatest loss of productivity cost which was RM152 940.00 (RM8496.67/patient). The result also indicates that there was statistically significant difference in cost of medication, lab tests, transportation and loss of productivity among 3 types of treatment options (Table 3) . Next, Figure 3 illustrates the effectiveness of the treatments which was measured by the number of patients achieved PASI-75 and/or BSA <5 and/or DLQI ≤5. TB treatment has the highest number of patients achieved PASI-75 and/or BSA <5 and/or DLQI ≤5 which was 8 out of 12 patients (67.7%), followed by TS with 33 out of 60 patients (55.0%) and TP with 8 out of 18 patients (44.4%). Table 4 shows the base-case results of the cost-effectiveness analysis from the societal perspective over a 6-month period. TS has been revealed as the most cost-effective modality as it yields the lowest cost per PASI-75 and/or BSA <5 and/ or DLQI ≤5, valued at RM9034.56. This is followed by TP treatment, which is valued RM28 080.71, and finally, TB treatment, valued at RM54,287.02. and effective response [58% (7/12)]). Figure 4A -B illustrates a Tornado diagram expressed in ICER. Dotted lines correspond to the ICER value in the base-case scenario. One-way sensitivity analysis pointed out the cost of biologics and loss of productivity cost as the most sensitive parameter of the model.
Discussion
This study has emerged as the first and pioneering economic evaluation in assessing the cost-effectiveness of 3 psoriasis treatments for moderate to severe psoriasis in Malaysia. Previous analyses of the cost-effectiveness of these interventions has yielded mixed results. Some evidence has suggested the biologic modality as the most cost-efficient option compared to other modalities. [30] [31] [32] Meanwhile, other works have indicated that the systemic treatment has generated the lowest cost per PASI response 33 whereas several studies have demonstrated phototherapy to be the most cost-effective regiment. Nevertheless, this particular work has suggested the TS treatment to be the most cost-effective modality, despite TB showing the best results in terms of effectiveness. This especially relevant as the cost-effectiveness analysis taking into account both cost and effectiveness in determining the most cost-effective strategy. The costs analysis in this study has demonstrated that the total cost of TS to be twice lesser than TB, whereas effectiveness difference has only been found to be at 13%. Hence, this indicates that the TS treatment modality is the most cost-effective regimen.
The inconsistent findings obtained in determining the most cost-effective treatment for moderate to severe psoriasis can be attributed to several factors. One of them includes different effectiveness measure, which is believed to be the main cause for the large variation in cost-effectiveness values displayed in this study versus Sizto et al. 35 The latter work has found that systemic medication (eg, cyclosporine) has exhibited the lowest cost/quality-adjusted life year from the societal perspective in the United Kingdom, valued at RM165 441.90 (£25 135). This is in comparison with the biologic regiment, which is valued between RM245 408.27 to RM279 688 (£37 284-£42 492). In this particular study, the cost/PASI-75 and/or BSA <5 and/or DLQI ≤5 for systemic treatment has also been found to be less than the biologic treatment, valued at RM9038.69 compared to RM52 659.51 respectively. Furthermore, the duration of time taken for the study to be undertaken is also capable of influencing the results. Pearce et al 36 have demonstrated the systemic agent to be the most cost-effective strategy in the United States, with the lowest cost/PASI-75 of RM2837.62 (US$623). However, that value is particularly less compared to The previous study has calculated cost and effectiveness for a systemic agent during a 12-week time period, as opposed to this study that has measured four systemic medications (ie, methotrexate, cyclosporine, acitretin and sulphasalazine) for 24 weeks. Therefore, a longer duration is capable of affecting the outcome, as both overall costs and the probability of treatment success are both increased. This is also justified by the work by Cabello Zurita et al 37 whereby approximately 33.3% of the patients being treated with methotrexate have achieved 75% reduction of psoriasis symptoms by week 12. The percentage has shown considerable increments to 34.9%, 44.7%, and 52.8% at week 16, 24, and 48 respectively.
The duration of the cost effectiveness study of the psoriasis treatment modalities defined in different works is also variable. Knight et al 38 have assessed cost-effectiveness of psoriasis treatments for 10 years, Verma et al 39 a long-time horizon is preferred, data associated with to the long-term experience with several psoriasis therapies is still lacking. Such information includes the annual drop-out rates from treatment, the 'remission' period, the efficacy of subsequent lines of treatment, the cost and incidence of side effects and the risk of hospitalization. 43 Furthermore, numerous studies focused on the economic evaluation of psoriasis treatments have typically compared 2 interventions only. 11, 32, [44] [45] [46] Out of the 19 studies that have differentiated the cost-effectiveness of disparate treatment options, only few studies have opted to evaluate in terms of 3 interventions, namely systemic, biologic and phototherapy. [32] [33] [34] [35] [36] Most of the recent analyses are generally dominated by studies evaluating the cost-effectiveness of biologic drugs. 40, 43, [47] [48] [49] [50] [51] This evaluation is especially relevant as the biologic regiment is commonly known as the best intervention in treating moderate to severe psoriasis, offering high safety profile, fewer side effects and increased patient's quality of life. Hence, a cost-effectiveness study is paramount to justify the need for biologic agents in the respective countries.
In this study, PASI-75 and/or BSA <5 and/or DLQI ≤5 has been considered as an outcome. These responses are widely used in studies involving psoriasis, with PASI, in particular, being underlined as the gold standard and meeting the criteria of methodological validity. 26, 27, 52, 53 Furthermore, the score has also been proven to be strongly correlated with BSA and DLQI. 56, 57 Previous studies have opted for utility measures, whereby the clinical outcome is converted to utility score using the EuroQol 5-dimensional questionnaire. Then, it is used to estimate the quality-adjusted life year. However, various evidence has demonstrated that PASI and DLQI responses to range between weak to moderately correlated with EuroQol 5-dimensional questionnaire. 58, 59 Hence, using utility values by means of PASI response has been linked to a high level of bias. 54 Additionally, another important information elicited from the findings of this study is that the cost of medication (ie, biologic and systemic) is the most sensitive parameters. Similarly, various previous works have highlighted the biologic medications as the highest contributor towards the overall cost of medication, 54 resulting in several-fold escalation of overall cost of treatments. 19, 54, 60 Similarly, analytical trends in systemic psoriasis treatment costs have revealed that biologic medications to exceed general inflation, with an incremental rate for biologic agents of 120% for etanercept, 103% for adalimumab and 53% for ustekinumab during the period 2004-2014. In contrast, their average annual increment within the same period is 8.2% for etanercept, followed by 9.2% (adalimumab) and 11.0% (ustekinumab). 61 Regardless, this study is also associated with several limitations. Firstly, the respondents have been recruited from 5 tertiary, government-run hospitals only and excluded patients who sought treatment in private clinics and hospitals. Hence, the data obtained may not be completely representative of all cases of moderate to severe psoriasis in Malaysia. Nevertheless, it has provided meaningful insight to clinicians anyway regarding resource utilization in managing psoriasis. Secondly, time duration utilised in this study is less than a year despite psoriasis being a long-term and chronic disease. Therefore, is important to establish a cost-effectiveness model that is capable of predicting changes and interruptions during treatment, as well as its effectiveness in many coming years. But, conducting and maintaining a long-term study is a very difficult task due to the high dropout rate and mid-treatment changes occurring. It is justifiable that high drop out rate could lead to selection bias that affects conclusion of the finding. Therefore, the findings of the study could be limited to the fact that TS is the most cost-effective treatment in Malaysia if majority of the patients are moderate psoriasis (PASI >10-20, BSA >10-30 and DLQI >10-20 as refers to the classification of disease severity by the guideline of the Management of Psoriasis Vulgaris in Malaysia). 6 Thirdly, the associated side effect costs have also been excluded. Generally, the side effects of a treatment are very complex, especially for diseases involving many comorbidities like psoriasis. This renders costing calculations to be a demanding and challenging task, despite the inevitable importance of the role that side effects play during treatment decision-making.
Conclusion
Treatment for moderate to severe psoriasis causes considerable direct and indirect costs. TB treatment exhibited highest effectiveness but, TS treatment is considered the most costeffective strategy in Malaysia situation in where majority of the patients are moderate psoriasis. The important finding of this study is to guide policy makers to determine the first line treatment considering its cost and effectiveness for moderate to severe psoriasis in Malaysia, allows hospitals to justify and provide the essential capitals for further research and development as well as adoption of better treatment options. Future cost-effective analysis should provide information on the long-term experience with psoriasis interventions and manage the uncertainty associated with key drivers of the cost effectiveness of psoriasis treatments.
